@article{ATM10619,
author = {Masroor Mirza and Jamsheed Javid and Prasant Yadav and Anant Mohan and Prakash Chandra Ray and Alpana Saxena},
title = {Detection of HER2 polymorphism and expression using circulating DNA and RNA as a tool in lung adenocarcinoma patients: a case control study},
journal = {Annals of Translational Medicine},
volume = {4},
number = {11},
year = {2016},
keywords = {},
abstract = {Background: Circulating DNA and RNA is an important prognostic tool for noninvasive malignant disease detection and in disease prognosis. Study aimed to evaluate the possible prognostic role of HER2 (-3444C/T) promoter polymorphism and its mRNA expression in Lung adenocarcinoma patients using circulating DNA and RNA.
Methods: One hundred newly diagnosed lung adenocarcinoma patients and 100 age and sex matched healthy controls were included and allele specific (AS) polymerase chain reaction (PCR) was used for genotyping and expression was analyzed by quantitative real time PCR. Overall survival of patients was analyzed by Kaplan-Meier method.
Results: We observed a statistically significant difference in the frequency of HER2 CC, CT, and CT genotype among lung adenocarcinoma cases vs. healthy controls (P=0.001). Compared to the CC genotype, OR 2.51 (1.4–4.51), 5.97 (1.17–30.41) and RR 1.56 (1.17–2.07), 2.83 (0.82–9.73) for heterozygous CT and homozygous TT genotypes suggesting possible dominant effect on risk of lung adenocarcinoma. Cases with CC genotype showed 9.29 fold increased mRNA expression while cases with heterozygous CT and homozygous TT genotype showed 16.26, 16.72 fold increased mRNA expression (P},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/10619}
}